AstraZeneca, Abbott partner on combo drug

Share this article:
AstraZeneca and Abbott Laboratories said they plan to co-develop and market a combination cholesterol drug. The pill would combine AZ’s cholesterol-lowering drug Crestor with Abbott’s ABT-335, currently in Phase III clinical trials for raising HDL or "good" cholesterol and reducing triglycerides. The companies say they also will evaluate a combination drug based on Crestor and Abbott’s TriCor, which is approved for lowering triglycerides. TriCor is licensed to Abbott for US marketing by Solvay. ABT-335 is a next-generation version of TriCor. Final selection between the two drugs will be made based upon data generated from initial studies, the companies said, with FDA filing expected in 2009.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.